) --

Cambrex Corporation



) hit a new 52-week high Friday as it is currently trading at $8.16, above its previous 52-week high of $8.12 with 189,043 shares traded as of 1:40 p.m. ET. Average volume has been 291,200 shares over the past 30 days.

Cambrex has a market cap of $227.3 million and is part of the

health care

sector and


industry. Shares are up 7.8% year to date as of the close of trading on Thursday.

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics. It primarily involves in the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The company has a P/E ratio of 14.6, below the average drugs industry P/E ratio of 15.4 and below the S&P 500 P/E ratio of 17.7.

  • Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Cambrex as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and attractive valuation levels. However, as a counter to these strengths, we find that the company has not been very careful in the management of its balance sheet. You can view the full

Cambrex Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center